Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus PYOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus PYOCIDIN.
CHLOROMYXIN vs PYOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
CHLOROMYXIN is not a recognized drug. No data available.
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Category C
Category C
Antibiotic
Antibiotic